血清性尿血症候群における血小板活性化因子の尿による排泄
A Benigni1, P Boccardo, M Noris
1Division of Nephrology, Ospedali Riuniti Bergamo, Italy.
Lancet (London, England)
|April 4, 1992
まとめ
尿血小板活性化因子 (PAF) は,急性期において,血液分解性尿血症候群 (HUS) の小児において有意に高かった. 回復後,尿中のPAF濃度が低下し,HUS疾患の活性を示す可能性があることを示唆しています.
科学分野:
- ネフロロジーはネフロロジーを用います.
- 小児科は小児科です.
- 免疫学 免疫学とは
背景:
- ヘモリティック・ウレミック・シンドローム (HUS) は,血小板の活性化と球損傷を伴う.
- 血小板活性化因子 (PAF) は,HUSの病原性に関与しています.
- 尿経PAFの排泄は,HUS患者では広く研究されていない.
研究 の 目的:
- HUS.を持つ子供の尿中のPAFレベルを調査する.
- 尿中のPAFがHUS疾患の活動と相関するかどうかを判断する.
主な方法:
- 尿中のPAF濃度を測定するために,放射性免疫測定法が使用されました.
- 10人のHUSの子どもと10人の健康な対照群を研究した.
- 尿サンプルは,急性HUSおよび回復後の時期に採取した.
主要な成果:
- 尿中のPAF濃度は,対照群と比較して急性期HUS患者において有意に高かった (2.04 vs 0.72 ng/mgクレアチニン,p < 0.05).
- 回復したHUS患者の尿中のPAFレベルは,対照レベルに類似していました.
- 急性HUSのときに尿中のPAFが上昇すると,血小板活性化と小球球損傷を示す可能性があります.
結論:
- 小便のPAFは,小児におけるHUSの急性期間に著しく上昇します.
- 尿中のPAFは,HUS疾患の活動のための潜在的なバイオマーカーとして機能する可能性があります.
- HUSの病理生理学におけるPAFの役割を調べるためにさらなる研究が必要である.
関連する概念動画
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Role of Hematopoietic Growth Factors
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
Thrombopoietin (TPO), mainly released by the liver,...
Coagulation
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...


